Abstract:Purpose of review: This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3). Recent findings: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF is now theoretically sufficient to diagnose narcolepsy type 1, as it is a highly specific and sensitive biomarker. Conversely, other central hypersomnias are less well-defined disorders with variability in the phenotype, and few reliable biomarkers have been discovered so far. The epidemiologic observation that influenza A (H1N1) infection and vaccination are potential triggering factors of narcolepsy type 1 (discovered during the 2009 H1N1 pandemic) has increased interest in this rare disease, and progress is being made to better understand the process (highly suspected to be autoimmune) responsible for the destruction of hypocretin neurons. Treatment of narcolepsy remains largely symptomatic, usually initially with modafinil or armodafinil or with higher-potency stimulants such as methylphenidate or amphetamines. Several newer wake-promoting agents and psychostimulants have also been developed, including sodium oxybate, which has a role in the treatment of cataplexy and as an adjunctive wake-promoting agent, and pitolisant, a selective histamine H3 receptor inverse agonist that is currently only available in Europe. Summary: Although far less common than many other sleep disorders, central hypersomnias are among the most severe and disabling diseases in the field of sleep medicine, and their early recognition is of major importance for patients, especially children, to maximize their quality of life and functioning in activities of daily living.

Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation

Research progress of immunologic mechanism of narcolepsy

Advances in narcolepsy

Sleepiness That Cannot Be Overcome: Narcolepsy And Cataplexy

Narcolepsy and Other Central Hypersomnias

[Narcolepsy in adults: Definition, etiology and treatment]

Genetics and epigenetics of rare hypersomnia

Recent insights into the pathophysiology of narcolepsy type 1

Pediatric Narcolepsy Type 1: A State-of-the-Art Review

Type 1 narcolepsy: a CD8(+) T cell-mediated disease?

Impaired cognition in narcolepsy: clinical and neurobiological perspectives

Infection, vaccination and narcolepsy type 1: Evidence and potential molecular mechanisms

Connecting clinicians and patients: The language of narcolepsy

Narcolepsy and pediatric acute-onset neuropsychiatric syndrome: A case report that suggests a putative link between the two disorders

Connecting the dots: An updated review of the role of autoimmunity in narcolepsy and emerging immunotherapeutic approaches

Respiratory Regulation in Narcolepsy

0002 FINE MAPPING GENOME-WIDE ASSOCIATION IN NARCOLEPSY DEFINES NOVEL DISEASE MECHANISMS

From past to future: 50 years of pharmacological interventions to treat narcolepsy

Narcolepsy, orexins and respiratory regulation

Multiple Sleep Latency Test/Maintenance of Wakefulness Test and Central Hypersomnias: Evolving Diagnostic and Therapeutic Approaches

Hits and misses with animal models of narcolepsy and the implications for drug discovery